Amgen Chooses To Settle In US Soliris IPR Tussle
Victory Could Have Led To 2022 Market Entry
Amgen’s burgeoning biosimilar presence continues to grow apace and now the company has eyes firmly on the US market for eculizumab after brokering a deal with originator Alexion. The biosimilars developer chose to settle on three of Alexion’s patents ahead of a trial later this year.
You may also be interested in...
Samsung Bioepis is the latest company to stare down a lawsuit from Genentech over Avastin patents in the US. The Korean firm is aiming to be amongst the early biosimilar movers, after the market formed a year ago.
Sandoz has failed to overturn on appeal an invalidity ruling for two patents covering Enbrel in the US, barring a path to market for its Erelzi biosimilar, potentially until patent expiry in 2029.
Biosimilar competition to Regeneron’s Eylea (aflibercept) eye-disease biologic may emerge as early as 2023, with at least three firms moving candidates to Phase III development following Samsung Bioepis’ study initiation.